2023考研英語閱讀重塑皮拉馬爾
Reimagining Piramal
重塑皮拉馬爾
Blood, sweat, but no tears
流血，流汗，不流淚
An old Indian business house still has fire in itsbelly
作為印度一家老牌企業，皮拉馬爾依然激情澎湃
WHEN his brother s death in 1984 is mentioned, Ajay Piramal , a big, calm man, still lookssad.
提起1984年他哥哥之死時，阿賈伊?皮拉馬爾，這個高大冷靜的漢子，仍然是面露悲傷。
That tragedy propelled him at the age of 29 to the helm of one of India s big, old and flaggingbusiness houses.
那場悲劇將29歲的他推上了企業舵手的位子，執掌印度一家正在衰落的老資格大型企業。
Since then he has run it with a stark lack of sentimentality and with outrageous success.
從那時起，他在企業運營上沒有半點多愁善感，取得了巨大的成功。
Having sold the crown jewelsa generic-drugs outfitin 2010, for $3.8 billion, he is nowbusy re-imagining the family firm for the third time.
2010年他將企業皇冠上的珠寶非專利藥部門以38億美元售出，現在，他正忙于家族企業的第三次重整。
Given his record, it is worth paying attention.
以他過去的記錄來看，此事值得關注。
Piramal s first reincarnation came in the 1980s.
80年代，皮拉馬爾經歷了第一次重生。
The main textiles business was dying.Its workers were striking; its mills were outdated and packed into central Mumbai.
企業的主業紡織業正走向衰亡。企業的工人在罷工，陳舊的工廠擁擠在孟買市中心。皮拉馬爾先生削減了員工，搬遷了工廠。
Mr Piramal cut staff and moved out. Today the land he freed forms a new business district,where snazzy towers sprout from the ruins of old factories.
今天，當年騰出來的地塊形成了新的商業區，一座座時髦的高塔如雨后春筍般從老廠房的廢墟上拔地而起。
Some textiles clans have since lived off their property. Others began new adventures.
一些紡織企業從此吃上老本，其他的轉去開拓新的生意。
A branch of the Wadia family, old Mumbai royalty, started an airline.
孟買歷史悠久的瓦蒂亞皇室家族4旗下一個分支，開始經營航空業。
Piramal began making generic drugs for Indians, buying in 1988 the local unit of a Britishfirm and then picking up similar operations from other foreign pharmaceutical firms whichhad lost hope in India.
皮拉馬爾則開始為印度百姓生產非專利藥，他于1988年收購了一家英國制藥公司的本地部門，之后，又輕松地與其他幾家對印度喪失信心的外國藥企完成了多宗類似交易。
Often multinationals move in a herd mentality, says Mr Piramal.
通常，跨國公司的行動帶有從眾心理，皮拉馬爾先生說道。
By the late 2000s Piramal was India s third-largest drugs firm.
到本世紀頭十年的末期，皮拉馬爾成為了印度第三大制藥公司。
This second incarnation ended abruptly.
皮拉馬爾的第二次重整戛然而止。
In 2004, with his brother s sons grown up, the clan split, apparently amicably, with MrPiramal s nephews and their mother taking the property and textile units.
2004年，他哥哥的兒子們長大成人，家族也隨之分裂，皮拉馬爾的幾個侄兒和他們的母親分得房地產和紡織部門，表面上還是一團和氣。
In 2010 Abbott, an American drugs firm with a history of failing to crack India, bid apreposterous $3.8 billion for the Indian generic-drugs business, which had just $425m ofsales.
2010年，一直未能叩開印度市場大門的美國雅培制藥，對皮拉馬爾年銷售額不過4.25億美元的非專利藥部門開出了高得離譜的38億美元收購價格。
It was a stiff price, says the diplomatic Mr Piramal, who had not expected the bid and saysthe negotiations over price took only a few hours.
這是個高昂的報價，老練的皮拉馬爾說，他沒有料到這個出價，而且協商價格只用了幾個小時。
What now?
現在是個什么情況?
Mr Piramal has parked part of the proceeds by buying a stake in Vodafone s Indian arm, anarrangement that looks temporary.
皮拉馬爾先生將部分交易收益投入對沃達豐印度公司的股權收購中，貌似這只是暫時的安排。
He is a critic of crony capitalism in India, which limits his options.
他總是批評印度的裙帶資本主義，這使得他的選擇有限。
The boom in infrastructure in 2007-10, when well connected entrepreneurs milkedgovernment links, did not feel right, he says. Many are now in financial trouble and a few areunder investigation.
2007年至2010年，基礎設施建設蓬勃發展，人脈廣泛的企業家們與政府勾結而自肥，皮拉馬爾對此感覺不對勁。很多這類企業現在深陷財務危機，有一些正被調查。
Instead, Piramal has three new areas of emphasis.
相反，皮拉馬爾將重點放在三個新的領域。
One is a limited re-entry into property.
一個是有限地再次進軍房地產業。
Land prices have dropped as some Mumbai developers have become overstretched.
由于孟買一些開發商擴張過度，地價有所下跌。
And there has been a recent crackdown on the corrupt nexus between developers andofficials.
近期政府又打擊了一起官商勾結的腐敗問題。
People like us were at a disadvantage, he says.
像我們一樣的人吃了虧，他說到。
Now, at least for a while, they are not.
現在，至少暫時，他們沒有吃虧了。
The second new area is health-care services in America.
第二個新的領域是美國的醫療服務業。
On May 16th Piramal spent $635m on Decision Resources, a Massachusetts firm that analysesand crunches data on drugs and treatments.
五月十六日，皮拉馬爾向馬薩諸塞州一家名為決策資源的公司投資6.35億美元，該公司從事藥物與疾病治療的數據分析與處理業務。
He is betting that treatments will become ever more specialised and that the buyers of drugsin Americastate bodies and insurance firmswill become even more finicky andcost-conscious.
他的判斷是，疾病治療將會更加專業化，而美國的藥品買家將會更加挑剔、更加注重節省成本。
Drug firms are outsourcing this kind of activity.
制藥公司將此類業務進行外包。
That logic seems to embody a conventionally gloomy view of the pharmaceuticalsindustry, which seems unable to discover enough new drugs or to protect its patents on oldones.
這種邏輯似乎體現了對于制藥業習以為常的悲觀看法，即人們認為制藥業無法開發出足夠多的新藥，并且也無法保護已研制出的藥品專利。
Piramal s third area of expansion is thus a surprise:
因此，皮拉馬爾的第三個擴張領域出人意料：
Mr Piramal wants to invent new blockbuster drugs.
皮拉馬爾先生想要創造出有巨大影響的新藥。
Surely that is a business model as obsolete as inner-city textile mills?
這不是和在城中心建紡織廠同樣過時的商業模式嗎?
Mr Piramal thinks not, especially if research and clinical trials can be shifted to India, wherecosts could be as little as a tenth of those in the rich world.
皮拉馬爾先生并不這么認為，尤其是考慮到如果能將藥物研發與臨床試驗從發達國家遷移到印度進行，成本將會降至十分之一。
We re hopeful that we ll discover new drugs and make breakthroughs, he says.
我們對發現新藥并取得突破充滿信心，他說。
We take a contrarian view.
我們的觀點是逆勢而為。
詞語解釋
1.belly n.腹部
My belly is empty.
我肚子餓了。
2.outrageous a.過分的;駭人的
The princess spent an outrageous amount onclothes.
公主在穿著上揮霍無度。
3.reincarnation n.轉世;再生
Buddhists believe in reincarnation.
佛教徒相信投胎轉世。
4.property n.財產;所有物;地產，房地產
The property was returned to the original owner.
財產已歸還原主。
5.pharmaceutical a.制藥的;配藥的
Her brother is interested in pharmaceutical botany.
她的哥哥對藥草感興趣。
Reimagining Piramal
重塑皮拉馬爾
Blood, sweat, but no tears
流血，流汗，不流淚
An old Indian business house still has fire in itsbelly
作為印度一家老牌企業，皮拉馬爾依然激情澎湃
WHEN his brother s death in 1984 is mentioned, Ajay Piramal , a big, calm man, still lookssad.
提起1984年他哥哥之死時，阿賈伊?皮拉馬爾，這個高大冷靜的漢子，仍然是面露悲傷。
That tragedy propelled him at the age of 29 to the helm of one of India s big, old and flaggingbusiness houses.
那場悲劇將29歲的他推上了企業舵手的位子，執掌印度一家正在衰落的老資格大型企業。
Since then he has run it with a stark lack of sentimentality and with outrageous success.
從那時起，他在企業運營上沒有半點多愁善感，取得了巨大的成功。
Having sold the crown jewelsa generic-drugs outfitin 2010, for $3.8 billion, he is nowbusy re-imagining the family firm for the third time.
2010年他將企業皇冠上的珠寶非專利藥部門以38億美元售出，現在，他正忙于家族企業的第三次重整。
Given his record, it is worth paying attention.
以他過去的記錄來看，此事值得關注。
Piramal s first reincarnation came in the 1980s.
80年代，皮拉馬爾經歷了第一次重生。
The main textiles business was dying.Its workers were striking; its mills were outdated and packed into central Mumbai.
企業的主業紡織業正走向衰亡。企業的工人在罷工，陳舊的工廠擁擠在孟買市中心。皮拉馬爾先生削減了員工，搬遷了工廠。
Mr Piramal cut staff and moved out. Today the land he freed forms a new business district,where snazzy towers sprout from the ruins of old factories.
今天，當年騰出來的地塊形成了新的商業區，一座座時髦的高塔如雨后春筍般從老廠房的廢墟上拔地而起。
Some textiles clans have since lived off their property. Others began new adventures.
一些紡織企業從此吃上老本，其他的轉去開拓新的生意。
A branch of the Wadia family, old Mumbai royalty, started an airline.
孟買歷史悠久的瓦蒂亞皇室家族4旗下一個分支，開始經營航空業。
Piramal began making generic drugs for Indians, buying in 1988 the local unit of a Britishfirm and then picking up similar operations from other foreign pharmaceutical firms whichhad lost hope in India.
皮拉馬爾則開始為印度百姓生產非專利藥，他于1988年收購了一家英國制藥公司的本地部門，之后，又輕松地與其他幾家對印度喪失信心的外國藥企完成了多宗類似交易。
Often multinationals move in a herd mentality, says Mr Piramal.
通常，跨國公司的行動帶有從眾心理，皮拉馬爾先生說道。
By the late 2000s Piramal was India s third-largest drugs firm.
到本世紀頭十年的末期，皮拉馬爾成為了印度第三大制藥公司。
This second incarnation ended abruptly.
皮拉馬爾的第二次重整戛然而止。
In 2004, with his brother s sons grown up, the clan split, apparently amicably, with MrPiramal s nephews and their mother taking the property and textile units.
2004年，他哥哥的兒子們長大成人，家族也隨之分裂，皮拉馬爾的幾個侄兒和他們的母親分得房地產和紡織部門，表面上還是一團和氣。
In 2010 Abbott, an American drugs firm with a history of failing to crack India, bid apreposterous $3.8 billion for the Indian generic-drugs business, which had just $425m ofsales.
2010年，一直未能叩開印度市場大門的美國雅培制藥，對皮拉馬爾年銷售額不過4.25億美元的非專利藥部門開出了高得離譜的38億美元收購價格。
It was a stiff price, says the diplomatic Mr Piramal, who had not expected the bid and saysthe negotiations over price took only a few hours.
這是個高昂的報價，老練的皮拉馬爾說，他沒有料到這個出價，而且協商價格只用了幾個小時。
What now?
現在是個什么情況?
Mr Piramal has parked part of the proceeds by buying a stake in Vodafone s Indian arm, anarrangement that looks temporary.
皮拉馬爾先生將部分交易收益投入對沃達豐印度公司的股權收購中，貌似這只是暫時的安排。
He is a critic of crony capitalism in India, which limits his options.
他總是批評印度的裙帶資本主義，這使得他的選擇有限。
The boom in infrastructure in 2007-10, when well connected entrepreneurs milkedgovernment links, did not feel right, he says. Many are now in financial trouble and a few areunder investigation.
2007年至2010年，基礎設施建設蓬勃發展，人脈廣泛的企業家們與政府勾結而自肥，皮拉馬爾對此感覺不對勁。很多這類企業現在深陷財務危機，有一些正被調查。
Instead, Piramal has three new areas of emphasis.
相反，皮拉馬爾將重點放在三個新的領域。
One is a limited re-entry into property.
一個是有限地再次進軍房地產業。
Land prices have dropped as some Mumbai developers have become overstretched.
由于孟買一些開發商擴張過度，地價有所下跌。
And there has been a recent crackdown on the corrupt nexus between developers andofficials.
近期政府又打擊了一起官商勾結的腐敗問題。
People like us were at a disadvantage, he says.
像我們一樣的人吃了虧，他說到。
Now, at least for a while, they are not.
現在，至少暫時，他們沒有吃虧了。
The second new area is health-care services in America.
第二個新的領域是美國的醫療服務業。
On May 16th Piramal spent $635m on Decision Resources, a Massachusetts firm that analysesand crunches data on drugs and treatments.
五月十六日，皮拉馬爾向馬薩諸塞州一家名為決策資源的公司投資6.35億美元，該公司從事藥物與疾病治療的數據分析與處理業務。
He is betting that treatments will become ever more specialised and that the buyers of drugsin Americastate bodies and insurance firmswill become even more finicky andcost-conscious.
他的判斷是，疾病治療將會更加專業化，而美國的藥品買家將會更加挑剔、更加注重節省成本。
Drug firms are outsourcing this kind of activity.
制藥公司將此類業務進行外包。
That logic seems to embody a conventionally gloomy view of the pharmaceuticalsindustry, which seems unable to discover enough new drugs or to protect its patents on oldones.
這種邏輯似乎體現了對于制藥業習以為常的悲觀看法，即人們認為制藥業無法開發出足夠多的新藥，并且也無法保護已研制出的藥品專利。
Piramal s third area of expansion is thus a surprise:
因此，皮拉馬爾的第三個擴張領域出人意料：
Mr Piramal wants to invent new blockbuster drugs.
皮拉馬爾先生想要創造出有巨大影響的新藥。
Surely that is a business model as obsolete as inner-city textile mills?
這不是和在城中心建紡織廠同樣過時的商業模式嗎?
Mr Piramal thinks not, especially if research and clinical trials can be shifted to India, wherecosts could be as little as a tenth of those in the rich world.
皮拉馬爾先生并不這么認為，尤其是考慮到如果能將藥物研發與臨床試驗從發達國家遷移到印度進行，成本將會降至十分之一。
We re hopeful that we ll discover new drugs and make breakthroughs, he says.
我們對發現新藥并取得突破充滿信心，他說。
We take a contrarian view.
我們的觀點是逆勢而為。
詞語解釋
1.belly n.腹部
My belly is empty.
我肚子餓了。
2.outrageous a.過分的;駭人的
The princess spent an outrageous amount onclothes.
公主在穿著上揮霍無度。
3.reincarnation n.轉世;再生
Buddhists believe in reincarnation.
佛教徒相信投胎轉世。
4.property n.財產;所有物;地產，房地產
The property was returned to the original owner.
財產已歸還原主。
5.pharmaceutical a.制藥的;配藥的
Her brother is interested in pharmaceutical botany.
她的哥哥對藥草感興趣。
